⌘K

Login Start Free

Home/Filings/4/0001104659-23-077669

4//SEC Filing

Menzel Garry E 4

Accession 0001104659-23-077669

CIK 0001621227other

View on SEC.gov Company Profile

Filed

Jul 2, 8:00 PM ET

Accepted

Jul 3, 5:03 PM ET

Size

5.6 KB

Accession

0001104659-23-077669

Insider Transaction Report

Form 4

Period: 2023-07-03

Adaptimmune Therapeutics PLCADAP

Director

Transactions

Award
Option to purchase Ordinary Shares
2023-07-03+981,463→ 981,463 total
Exercise: $0.16From: 2024-07-03Exp: 2033-07-03→ Ordinary Shares (981,463 underlying)

Footnotes (1)

[F1]The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Documents

1 file

4
tm2320409-5_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Adaptimmune Therapeutics PLC

CIK 0001621227

Entity typeother

Related Parties

1

filerCIK 0001556064

Filing Metadata

Form type: 4
Filed: Jul 2, 8:00 PM ET
Accepted: Jul 3, 5:03 PM ET
Size: 5.6 KB

View on SEC.gov